Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.39 AUD | +0.13% | +2.33% | +52.68% |
May. 21 | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
May. 20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.68% | 3.43B | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Transcript : Telix Pharmaceuticals Limited, H1 2021 Earnings Call, Aug 19, 2021